The skin cancer treatment market size is projected to reach US$ 19.53 billion by 2031 from US$ 11.79 billion in 2024. The market is expected to register a CAGR of 7.57% during 2025–2031.

Skin Cancer Treatment Market Analysis

The surging prevalence of skin cancer and growing approvals and robust pipeline of advanced therapies are propelling the use of skin cancer treatment. According to the American Cancer Society, there were ~212,200 new melanoma cases in the US in 2025, with 107,240 in situ and 104,960 invasive cases, ranking melanoma as the fifth most common cancer. This increasing incidence of skin cancer, such as melanoma, has created the demand for advanced therapies such as checkpoint inhibitors. Additionally, the adoption of personalized and combination therapies presents a significant opportunity for the skin cancer treatment market.

Skin Cancer Treatment Market Overview

North America is projected to dominate the skin cancer treatment market with the largest share, and Asia Pacific is expected to register a significant CAGR during the forecast period. The region includes prominent markets such as China, Japan, India, South Korea, Australia, and the broader Asia Pacific, and accounts for a significant share in the region’s growth. The incidence of skin cancer in some Asian countries is lower than in Western countries, which can be due to better melanin composition of the population. The 2024 report of the National Cancer Center of China states that basal cell carcinoma and squamous cell carcinoma are increasing in incidence, especially in coastal provinces like Fujian and Guangdong. 

The Australian Institute of Health and Welfare (AIHW) reports that in 2023, over 1.1 million Australians underwent treatment for nonmelanoma skin cancers under the Medicare Benefits Schedule (MBS). The same report mentioned that melanoma was responsible for ~15,000 new cases and over 1,300 deaths in 2022. 

Melanoma cases are on a steady rise in Japan, especially among the elderly, as reported by the National Cancer Center. According to the latest update from the cancer registry in 2024, skin cancer is one of the top 20 common cancers in Japan with an increasing trend in incidence, especially in males aged 60 and above.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Skin Cancer Treatment Market: Strategic Insights

Market Size Value in	US$ 10,388.57 million in 2022
Market Size Value by	US$ 18,277.71 million by 2030
Growth rate	CAGR of 7.32% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Skin Cancer Treatment Market Drivers and Opportunities

Market Drivers:

• Expanding Approvals and Pipeline of Advanced Therapies:

  Expanding approvals and a robust pipeline of advanced therapies, including new immunotherapy and targeted therapy options, provide more choices for patients with advanced or aggressive skin cancer.

• Rising Prevalence of Skin Cancer:

  The increasing number of melanoma and nonmelanoma skin cancer cases is fueling the growth of the skin cancer treatment market. This steady growth of skin cancer cases is becoming one of the primary factors steering the growth and diversification of the market.

• Rising Awareness about Early Detection:

  Skin cancer, particularly melanoma, is highly treatable when detected early. Early detection allows for less invasive and more effective treatments, such as surgical excision.

Market Opportunities:

• Expansion in Emerging Economies: Several countries in Asia Pacific, Latin America, and Africa offer growth opportunities in the skin cancer treatment market due to the increasing number of skin cancer cases and awareness about early detection

  .

• Rising Medical Tourism:

  Increasing medical tourism in developing countries such as China, India, Indonesia, Brazil, and Mexico offers affordable advanced care and treatments, 50–70% less than in the US and European countries.

• Personalized and Combination Therapies:

  Advanced therapies such as neoadjuvant immunotherapy (pre-surgical) funded under public healthcare schemes can dramatically improve survival outcomes in high-risk patients.

Skin Cancer Treatment Market Report Segmentation Analysis

The skin cancer treatment market is divided into different segments to give a clearer view of how it works, its growth potential, and the latest trends. Below is the standard segmentation approach used in most industry reports:

By Type:

• Melanoma:

  Melanoma is the second largest segment by type, widely driven by the increasing incidence of melanoma worldwide. WHO reported in 2022 that ~330,000 new melanoma skin cancer cases occur worldwide every year.

• Nonmelanoma:

  Nonmelanoma skin cancers are more frequent than melanoma skin cancer. Nonmelanoma comprises Merkel cell carcinoma, basal cell carcinomas, and squamous cell carcinomas. These are completely curable through surgery and are rarely lethal.

By Therapy Type:

• Immunotherapy:

  Clinical data shows immunotherapy treatments such as pembrolizumab have provided an approximately 34% 5-year overall survival rate in advanced melanoma patients, a remarkable improvement over older method.

• Targeted Therapy:

  Targeted therapy, which is a step above old-school chemotherapy, attacks specific molecular pathways responsible for cancer cell growth. The most groundbreaking success is the discovery of BRAF gene mutations, which are present in roughly 40-60% of melanoma cases.

• Chemotherapy:

  The main goal of chemotherapy is to eliminate cancer cells that divide quickly by using drugs that are toxic to cells. However, unlike targeted therapies, chemotherapy does not distinguish between healthy cells and cancer cells. As a result, chemotherapy is associated with a number of adverse effects.

• Radiation Therapy:

  In the case of skin cancer, patients who are not eligible for surgery or systemic treatments can benefit from radiation therapy. In advanced or inoperable tumors, radiation therapy also takes a palliative role in relieving symptoms such as pain, bleeding, or obstruction.

• Others:

  In addition, there are other materials such as neoprene and polyisoprene. Neoprene is widely used for making surgical gloves, providing an excellent protection barrier and proper fit and feel.

By End User:

• Dermatology Clinics
• Hospitals
• Diagnostics and Cancer Care Centers
• Others

By Geography:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

The skin cancer treatment market in North America is expected to hold a significant share of the market. An increasing number of surgical procedures and business expansion strategies by the market players are factors likely to drive the market.

Skin Cancer Treatment Market Report ScopeSkin Cancer Treatment Market Share Analysis by Geography

Asia Pacific is expected to grow the fastest in the next few years. Emerging markets in Latin America, the Middle East, and Africa also have many untapped opportunities for skin cancer treatment providers to expand.

The skin cancer treatment market grows differently in each region. This is because of factors such as increasing prevalence of chronic diseases, growing surgical procedures, and increasing adoption of infection-control strategies. Below is a summary of market share and trends by region:

1. North America

• Market Share:

  Holds a significant portion of the global market

• Key Drivers:

  • The high incidence of melanoma and other skin cancers owing to the excessive exposure to UV radiation in certain areas.
  • The presence of well-developed treatment options including immunotherapies and targeted therapies.
  • High healthcare expenditures, and structured reimbursement frameworks are also notable.

• Trends:

   Growing use of personalized medicine, the development and strong investment in new biologics and therapeutics, and ample funding for new drug discovery.

2. Europe

• Market Share:

  A considerable portion of the market is attributable to advanced healthcare and the quick uptake of new treatments

• Key Drivers:

  • The increasing number of non-melanoma and melanoma skin cancer cases.
  • Favorable government initiatives for cancer awareness and screening programs.
  • Availability of advanced radiotherapy technologies and clinical trial networks.

• Trends:

  Focus on precision oncology, combination therapy approaches (immunotherapy + targeted therapy), and integration of AI in dermatology diagnostics

3. Asia Pacific

• Market Share:

  Fastest-growing region with a rising market share every year

• Key Drivers:

  • Rapid improvements in healthcare infrastructure across China, India, and Southeast Asia.
  • A growing patient population due to rising outdoor exposure and limited use of protective measures.
  • Increasing government funding for cancer care and expansion of insurance coverage.

• Trends:

  Increase in medical travel for affordable cancer treatments, utilization of post-modern diagnostic imaging tools, and increasing collaborations with international pharmaceutical companies.

4. South and Central America

• Market Share:

  Developing market with consistent growth.

• Key Drivers:

  • Increasing incidences of skin cancer, particularly in high UV index regions like Brazil and Chile.
  • Expanding access to dermatology specialists and cancer care centers.
  • Import of advanced skin cancer drugs and equipment.

• Trends:

   Increased focus on awareness campaigns, medical tourism for affordable treatment, and gradual entry of immunotherapies into local markets.

5. Middle East and Africa

• Market Share:

  Although small, but growing quickly

• Key Drivers:

  • Expanding healthcare infrastructure supported by government funding.
  • Rising awareness campaigns around cancer prevention and early detection.
  • Increasing collaborations with global pharma players for clinical trial expansion.

• Trends:

   Government-backed initiatives for skin cancer prevention, investments in advanced oncology centers, and growing use of tele-dermatology for remote diagnosis.

Skin Cancer Treatment Market Players Density: Understanding Its Consequences on BusinessHigh Competition and Density of Markets

High Market Density and Competition

The competition is fierce with established companies such as Sanofi, AstraZeneca PLC, and Eli Lilly and Company. Regional and niche providers such as Sun Pharmaceutical Industries Ltd (Asia Pacific) and Takeda Pharmaceutical (Asia Pacific) also add to the competitive landscape across different regions.

This high level of competition urges companies to stand out by offering:

• Advanced Products
• Value-added services such as customization and sustainable solutions
• Competitive pricing models
• Compliance with regulatory guidelines

Opportunities and Strategic Moves

• Focusing on developing and clinically investigating novel combination therapies.
• Companies are moving towards noninvasive therapies such as topical and photodynamic therapy that reduce recovery time and side effects

• Established companies partner with biotechs, academic research institutions, and healthcare providers to hasten the development of therapies and their clinical adoption.

Major Companies Operating in the Skin Cancer Treatment Market Include: 

1. Merck KGaA      
2. Pfizer Inc   
3. Novartis AG  
4. Bristol-Myers Squibb Co    
5. Amgen Inc    
6. Hoffmann-La Roche Ltd       
7. Regeneron Pharmaceuticals Inc     
8. GSK Plc    
9. Iovance Biotherapeutics Inc    
10. Genentech Inc 

Disclaimer: The above companies are not listed in a ranked order.

Other companies analysed during the course of research:

1. Sanofi
2. Sun Pharmaceutical Industries Ltd
3. Eli Lilly and Company
4. AstraZeneca PLC
5. Takeda Pharmaceutical Company Limited
6. Ipsen Pharma
7. Varian Medical Systems Inc.
8. Kyowa Kirin Co. Ltd.
9. Elekta AB
10. Aqua Pharmaceuticals
11. iCAD Inc.
12. AB Science
13. Cellceutix Corporation
14. Eisai Co. Ltd.
15. Otsuka Pharmaceutical Co. Ltd.

Skin Cancer Treatment Market News and Recent Developments

• US Food and Drug Administration Approved Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma.
• Novartis signed US$ 20 million licensing deal with Erasca to take the naporafenib melanoma therapy into mid-stage development.

Skin Cancer Treatment Market Report Coverage and Deliverables

The "Skin Cancer Treatment Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Skin Cancer Treatment Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Skin Cancer Treatment Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST and SWOT analysis
• Skin Cancer Treatment Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Skin Cancer Treatment Market
• Detailed company profiles